Edgewise Therapeutics, Inc. EWTX R2K

Healthcare · Biotechnology · United States

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Market & Price

Market Cap

$3.68B

Current Price

$34.16

High / Low (52W)

$38.01 / $12.61

Beta

0.25

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$4.59

Price to Book

7.44

P/S

EV/EBITDA

-16.10

Dividend Yield

Profitability & Returns

ROCE

-36.44%

ROE

-38.14%

ROA

-25.64%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.46

EPS (TTM)

$-1.66

Balance Sheet & Liquidity

Debt/Equity

0.77

Quick Ratio

22.16

Current Ratio

22.61

Debt

$3.79M

Total Assets

$552.60M

Current Assets

$543.38M

Working Capital

$516.01M

Ownership

Promoter Holding

0.45%

Chg in Prom Hold

FII / Inst Holding

113.98%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$3.18B

Total Revenue (TTM)

EBITDA

$-197.45M

Free Cash Flow

$-90.52M

Operating Cash Flow

$-148.49M

Shares Outstanding

107.59M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-49.36%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -49.4% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	EWTX Edgewise Therapeutics, Inc. R2K	34.16	-	$3.68B	-	-36.44%	-38.14%	-	-49.36%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45.96M	42.61M	46.86M	55.98M	54.12M
Operating Income	-3.25M	-3.96M	-3.64M	-6.86M	-10.46M	-13.08M	-14.83M	-16.49M	-18.26M	-25.70M	-25.34M	-29.45M	-34.75M	-38.11M	-40.43M	-45.96M	-42.61M	-46.86M	-55.98M	-54.12M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-45.41M	-42.04M	-46.29M	-55.40M	-53.52M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-40.80M	-36.12M	-40.67M	-50.22M	-49.01M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.19M	-3.95M	-3.64M	-6.82M	-10.35M	-12.95M	-14.66M	-16.07M	-17.50M	-22.84M	-21.47M	-25.71M	-28.52M	-31.50M	-34.13M	-40.80M	-36.12M	-40.67M	-50.22M	-49.01M
Diluted EPS	-	-	-	-4.37	-0.21	-0.26	-0.30	-0.32	-0.34	-0.36	-0.34	-0.41	-0.33	-0.34	-0.36	-0.43	-0.34	-0.39	-0.47	-0.46
R&D Expense	2.97M	3.64M	3.24M	5.36M	7.86M	9.88M	11.12M	12.40M	13.89M	19.88M	19.56M	23.79M	27.69M	30.68M	32.22M	36.76M	33.56M	37.48M	-	42.65M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	-	-	71.66M	114.36M	158.83M	191.41M
Operating Income	-17.19M	-	-71.66M	-114.36M	-158.83M	-191.41M
EBITDA	-	-	-71.12M	-112.62M	-156.54M	-189.14M
Interest Expense	-	-	-	-	-	-
Pretax Income	-	-	-67.64M	-100.16M	-133.81M	-167.79M
Tax Provision	-	-	-	-	-	-
Net Income	-17.12M	-	-67.64M	-100.16M	-133.81M	-167.79M
Diluted EPS	-23.17	-1.14	-0.31	-1.57	-0.42	-
R&D Expense	14.98M	32.19M	54.03M	90.91M	126.97M	151.39M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-49.36%
1 Year:	-

Stock Price Performance

1 Year:	+139.22%
6 Months:	+41.98%
3 Months:	+12.22%
1 Month:	+12.18%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	131.14M	-	367.10M	340.04M	486.82M	552.60M
Current Assets	-	-	-	357.00M	327.00M	475.48M	543.38M
Cash & Equivalents	-	104.92M	-	21.99M	86.10M	41.67M	61.15M
Inventory	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-
Total Liabilities	-	4.34M	-	20.39M	21.20M	27.60M	30.35M
Current Liabilities	-	4.34M	-	16.59M	16.77M	23.86M	27.37M
Long Term Debt	-	-	-	-	-	-	-
Total Debt	-	-	-	4.41M	5.41M	4.74M	3.99M
Total Equity	-16.85M	-33.42M	-	346.72M	318.83M	459.22M	522.26M
Shares Outstanding	-	-	-	63.26M	70.45M	94.84M	106.25M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-14.63M	-	-52.63M	-91.95M	-109.03M	-143.82M
Investing Cash Flow	-24.38M	-	-70.58M	102.89M	-184.66M	-32.79M
Financing Cash Flow	120.28M	-	129.64M	53.17M	249.25M	196.09M
Capital Expenditure	-203.00K	-	-5.55M	-5.75M	-1.31M	-256.00K
Free Cash Flow	-14.84M	-	-58.18M	-97.69M	-110.34M	-144.07M
Net Change in Cash	-	-	6.43M	64.10M	-44.43M	19.48M

Ratios (Annual)

Figures in %.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-
ROE %	51.2%	-	-19.5%	-31.4%	-29.1%	-32.1%
ROCE %	-13.6%	-	-20.4%	-35.4%	-34.3%	-36.4%

Shareholding Pattern

Insiders

0.45%

Institutions

113.98%

Public Float

114.50%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Orbimed Advisors LLC.	14.42%	15.52M	$530.11M
2	RA Capital Management, L.P.	9.69%	10.43M	$356.24M
3	Paradigm Biocapital Advisors LP	6.85%	7.37M	$251.59M
4	Baker Bros. Advisors, LP	6.11%	6.58M	$224.63M
5	Blackrock Inc.	6.02%	6.47M	$221.12M
6	Janus Henderson Group PLC	5.50%	5.92M	$202.08M
7	Novo Holdings A/S	4.97%	5.35M	$182.76M
8	Driehaus Capital Management, LLC	4.16%	4.48M	$152.97M
9	Siren, L.L.C.	4.12%	4.43M	$151.34M
10	Perceptive Advisors Llc	4.11%	4.42M	$151.12M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EWTX

No recent headlines available.

EWTX · Healthcare